BIOMERICA INC 10-K

ITEM 9A. CONTROLS AND PROCEDURES Attached as exhibits to this Form 10-K are certifications of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) that are required in accordance with Rule 13a-14 of the Exchange Act. This “Disclosure Controls and Procedures” section includes information concerning the controls and controls evaluation referred to in the certifications. EVALUATION OF DISCLOSURE CONTROLS Our management evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act as of the end of the period covered by this report. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives and the CEO and CFO have concluded that our disclosure controls and procedures are effective at the “reasonable assurance” level. Based on that evaluation the CEO and CFO concluded that information required to be disclosed in the reports that we file and submit under the Exchange Act is (1) recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms; and (2) accumulated and communicated to the Company’s management, including its CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Company management, including the CEO and CFO concluded that, as of May 31, 2022, the Company's internal control over financial reporting was effective. CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING There have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during the quarter ended May 31, 2022, that have materially affected, or that are reasonably likely to affect, our internal control over financial reporting. MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING Company management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company's internal control over financial reporting is designed to provide reasonable assurance to the Company's management and Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. A Company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements. The effectiveness of any system of internal control over financial reporting is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures. Because of these inherent limitations, internal control over financial reporting cannot provide absolute assurance regarding the reliability of financial reporting and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Company management, with the participation of the CEO and the CFO, evaluated the effectiveness of the Company's disclosure controls and procedures as defined in Rules 13(a)-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. In making this assessment, Management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control - Integrated Framework (2013). Based on this assessment, management, with the participation of the CEO and CFO, believes that, as of May 31, 2022, the Company's internal control over financial reporting was effective based on those criteria. 30 Company management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures and its internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing improvements, as necessary and as funds allow. Note: This 10-K does not include an attestation report of the Company's independent registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's independent registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this 10-K. ITEM 9B. OTHER INFORMATION. None. PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE . This information is incorporated by reference to the Company's proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2022. ITEM 11. EXECUTIVE COMPENSATION This information is incorporated by reference to the Company's proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2022. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS This information is incorporated by reference to the Company's proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2022. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE Other information regarding related transactions is incorporated by reference to the Company's proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company's fiscal year ended May 31, 2022. ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES Please refer to the Company’s proxy statement for its 2022 Annual Meeting of Stockholders, which will be filed not later than 120 days after the end of the Company’s fiscal year ended May 31, 2022. PART IV ITEM 15. EXHIBITS LIST AND FINANCIAL SCHEDULES The following documents are filed as part of this Annual Report on Form 10-K: 1. Consolidated Financial Statements Reference is made to the Index to the consolidated financial statements as set forth on page FS-1 of this Annual Report on Form 10-K. 2. Consolidated Financial Statement Schedules All schedules have been omitted as the pertinent information is either not required, not applicable, or otherwise included in the financial statements and notes thereto. 3. Exhibits See below. 31 Exhibit No. Description 3.1 First Amended and Restated Certificate of Incorporation of Registrant filed with the Secretary of State of Delaware on August 1, 2000 (incorporated by reference to Exhibit 3.8 filed with the Registrant's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2000). 3.2 Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 filed with Amendment No. 1 to Registration Statement on Form S-1, Commission File No. 2-83308). 4.1 Specimen Stock Certificate of Common Stock of Registrant (incorporated by reference to Exhibit 4.1 filed with Registrant's Registration Statement on Form SB-2, Commission No. 333-87231 filed on September 16, 1999). 10.1 Standard Industrial/Commercial Single-Tenant Lease, dated June 18, 2009, by and between Registrant and CNH, LLC for 17571 Von Karman Avenue, Irvine, CA 92614 (incorporated by reference to Exhibit 10.1 of the Company's August 31, 2009 Form 10Q filed October 15, 2009). 10.2 2014 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 22, 2015). 10.3 2017 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 10, 2018). 10.4 2020 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 21, 2021). 10.5 Form of Executive Stock Option Agreement (attached herein) 21.1 Listing of Subsidiaries (attached herein). 23.1 Consent of Independent Registered Public Accounting Firm (Haskell & White LLP). 23.2 Consent of Independent Registered Public Accounting Firm (PKF San Diego, LLP). 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended. 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended. 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended. 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended. 99.3 Registrant and Subsidiaries Consolidated Financial Statements. 32 101.INS XBRL Instance Document. 101.SCH XBRL Taxonomy Extension Schema Document. 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB XBRL Taxonomy Extension Label Linkbase Document. 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File. The certifications attached as Exhibits 32.1 and 32.2 accompany this Annual Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing. 33 SIGNATURES In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOMERICA, INC. Registrant By /s/ Zackary S. Irani Zackary S. Irani, Chief Executive Officer Dated: August 29, 2022 In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated: Signature and Capacity /s/ Zackary S. Irani Date: August 29, 2022 Zackary S. Irani Director, Chief Executive Officer /s/ Steve Sloan Date: August 29, 2022 Steve Sloan Chief Financial Officer /s/ Allen Barbieri Date: August 29, 2022 Allen Barbieri Director, Vice-Chairman /s/ Jane Emerson, M.D., Ph.D. Date: August 29, 2022 Jane Emerson, M.D., Ph.D. Director /s/ Mark Sirgo, Pharm.D. Date: August 29, 2022 Mark Sirgo, Pharm.D. /s/ Catherine Coste, CPA Date: August 29, 2022 Catherine Coste, CPA Director 34 BIOMERICA, INC. AND SUBSIDIARIES TABLE OF CONTENTS Reports of Independent Registered Public Accounting Firm FS-2 – FS-3 CONSOLIDATED FINANCIAL STATEMENTS Consolidated Balance Sheets as of May 31, 2022 and 2021 FS-4 Consolidated Statements of Operations and Comprehensive Loss for the Years Ended May 31, 2022 and 2021 FS-5 Consolidated Statements of Shareholders' Equity for the Years Ended May 31, 2022 and 2021 FS-6 Consolidated Statements of Cash Flows for the Years Ended May 31, 2022 and 2021 FS-7 Notes to Consolidated Financial Statements FS-8 – FS-21 Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors Biomerica, Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Biomerica, Inc. (the “Company”) as of May 31, 2022, the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cash flows for the year then ended, and the related notes (collectively, the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of May 31, 2022, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current-period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate. Evaluation of Inventory Reserves Critical Audit Matter Description As of May 31, 2022, the Company recorded reserves for slow-moving and obsolete inventories of approximately $846,000. As described in Note 2 to the consolidated financial statements, management periodically reviews inventories for excess quantities and obsolescence by evaluating quantities on hand and the physical condition and technical functionality of inventories, as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. Auditing the Company’s estimates for slow-moving and obsolete inventories was challenging due to the inherently judgmental nature of forecasting future sales and usage of a significant number of diverse inventory components. How the Critical Audit Matter Was Addressed in the Audit To test the valuation and accuracy of the Company’s inventory reserve estimates, our audit procedures included : ● Obtaining an understanding of the Company’s inventory reserve estimation processes and key internal controls and assessing their appropriateness; ● Observing and testing the Company’s year-end physical inventory counts; ● Testing the accuracy of key data inputs that are the primary drivers for determining the quantitative inventory reserves; these inputs included inventory quantities on hand, historical and expected sales and usage of inventory components, and estimated inventory reserve percentages; and ● Inquiring of any qualitative adjustments to inventory reserves deemed necessary by management and assessing their appropriateness. /s/ Haskell & White LLP HASKELL & WHITE LLP ( 200 ) We have served as the Company’s auditor since 2022. Irvine, California August 29, 2022 FS-2 Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors and Shareholders Biomerica, Inc. and Subsidiaries Irvine, California Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Biomerica, Inc. (a Delaware Corporation) and Subsidiaries (the “Company”) as of May 31, 2021, the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cash flows for the year ended May 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of May 31, 2021, and the results of its operations and its cash flows for the year ended May 31, 2021, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below are matters arising from the May 31, 2021 audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. Evaluation of Inventory and Accounts Receivable Allowances The Company recorded allowances for inventory and accounts receivable of approximately $1,600,000 and $840,000, respectively, as of May 31, 2021, primarily related to COVID-19 inventory items that have been slow moving and accounts receivable from foreign customers where collectability is questionable. As described in Note 2, these allowances are adjusted based on management’s ongoing evaluations and assessments based on current conditions. Auditing the Company’s estimates for inventory and accounts receivable allowances was challenging due to the assumptions made by management based on anticipated future results of customers and marketplace developments. We obtained an understanding and evaluated the assumptions, criteria and process used by management to determine the allowances for inventory items and accounts receivable. To test the valuation and accuracy of allowances for inventory and accounts receivable, our audit procedures included, among others, observation and testing of the cost and the valuation allowance for inventory items on hand, examining recent sales of items, testing of aging of accounts receivable balances, confirmation, and testing of subsequent cash receipts on accounts receivable, and discussions with management. /s/PKF San Diego, LLP (formerly PKF, LLP) We served as the Company’s auditor from 2004 to 2021. San Diego, California August 27, 2021, except for the effect of the restatement disclosed in Note 11 of the May 31, 2021 consolidated financial statements, as to which the date is October 14, 2021 FS-3 Table of Contents BIOMERICA, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS May 31, 2022 2021 Assets Current Assets: Cash and cash equivalents $ 5,916,983 $ 4,199,311 Accounts receivable, less allowance for doubtful accounts of $ 153,231 and $ 837,415 as of May 31, 2022 and 2021, respectively 773,818 1,455,051 Inventories, net 2,416,447 3,206,255 Prepaid expenses and other 320,283 370,290 Total current assets 9,427,531 9,230,907 Property and equipment, net of accumulated depreciation and amortization of $ 1,305,360 and $ 1,972,357 as of May 31, 2022 and 2021, respectively 214,487 310,520 Right of use assets, net of accumulated amortization of $ 724,802 and $ 469,077 as of May 31, 2022 and 2021, respectively 1,301,834 1,553,081 Investments 165,324 165,324 Intangible assets, net of accumulated amortization of $ 18,994 and $ 126,769 as of May 31, 2022 and 2021, respectively 169,516 294,830 Other assets 95,588 264,151 Total Assets $ 11,374,280 $ 11,818,813 Liabilities and Shareholders' Equity Current Liabilities: Accounts payable and accrued expenses $ 972,372 $ 583,380 Accrued compensation 646,944 388,896 Advance from customers 50,670 - Lease liability, current portion 341,296 327,944 Total current liabilities 2,011,282 1,300,220 Lease liability, net of current portion 1,038,284 1,291,570 Total Liabilities 3,049,566 2,591,790 Commitments and contingencies (Notes 6 and 9) Shareholders' Equity: Preferred stock, Series A 5% convertible, $ 0.08 par value, 571,429 shares authorized, none issued and outstanding as of May 31, 2022 and 2021 - - Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding as of May 31, 2022 and 2021 - - Common stock, $ 0.08 par value, 25,000,000 shares authorized, 12,867,924 and 12,307,157 issued and outstanding at May 31, 2022 and 2021, respectively 1,029,432 984,571 Additional paid-in-capital 42,446,597 38,836,743 Accumulated other comprehensive loss ( 73,936 ) ( 47,956 ) Accumulated deficit ( 35,077,379 ) ( 30,546,335 ) Total Shareholders' Equity 8,324,714 9,227,023 Total Liabilities and Shareholders' Equity $ 11,374,280 $ 11,818,813 See accompanying notes to consolidated financial statements FS-4 Table of Contents . BIOMERICA, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the year ended May 31, 2022 2021 Net sales $ 18,871,409 $ 7,199,027 Cost of sales ( 15,893,991 ) ( 6,832,742 ) Gross profit 2,977,418 366,285 Operating expenses: Selling, general and administrative 5,698,958 5,671,517 Research and development 1,812,424 2,194,461 Total operating expense 7,511,382 7,865,978 Loss from operations ( 4,533,964 ) ( 7,499,693 ) Other income: Dividend and interest income 26,639 66,863 Interest expense - ( 367 ) Total other income 26,639 66,496 Loss before income taxes ( 4,507,325 ) ( 7,433,197 ) Provision for income taxes ( 23,719 ) ( 13,057 ) Net loss $ ( 4,531,044 ) $ ( 7,446,254 ) Basic net loss per common share $ ( 0.36 ) $ ( 0.62 ) Diluted net loss per common share $ ( 0.36 ) $ ( 0.62 ) Weighted average number of common and common equivalent shares: Basic 12,673,245 11,928,941 Diluted 12,673,245 11,928,941 Net loss $ ( 4,531,044 ) $ ( 7,446,254 ) Other comprehensive loss, net of tax: Foreign currency translation ( 25,980 ) ( 8,115 ) Comprehensive loss $ ( 4,557,024 ) $ ( 7,454,369 ) See accompanying notes to consolidated financial statements FS-5 Table of Contents BIOMERICA, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY FOR THE YEARS ENDED MAY 31, 2022 AND 2021 Series A 5% Convertible Preferred Stock Additional Paid-in Capital Accumulated Other Comprehensive Loss Common Stock Accumulated Deficit Shares Amount Shares Amount Total Balances, May 31, 2020, restated 11,740,089 $ 939,205 321,429 $ 25,714 $ 36,388,056 $ ( 39,841 ) $ ( 23,100,081 ) $ 14,213,053 Exercise of stock options 86,750 6,940 - - 95,315 - - 102,255 Net proceeds from ATM 158,889 12,712 - - 998,763 - - 1,011,475 Foreign currency translation - - - - - ( 8,115 ) - ( 8,115 ) Conversion of preferred to common stock 321,429 25,714 ( 321,429 ) ( 25,714 ) - - - - Compensation expense in connection with options granted - - - - 1,354,609 - - 1,354,609 Net loss - - - - - - ( 7,446,254 ) ( 7,446,254 ) Balances, May 31, 2021, restated 12,307,157 984,571 - - 38,836,743 ( 47,956 ) ( 30,546,335 ) 9,227,023 Exercise of stock options 39,500 3,160 - - 74,200 - - 77,360 Net proceeds from ATM 521,267 41,701 - - 2,275,459 - - 2,317,160 Foreign currency translation - - - - - ( 25,980 ) - ( 25,980 ) Compensation expense in connection with options granted - - - - 1,260,195 - - 1,260,195 Net loss - - - - - - ( 4,531,044 ) ( 4,531,044 ) Balances, May 31, 2022 12,867,924 $ 1,029,432 - $ - $ 42,446,597 $ ( 73,936 ) $ ( 35,077,379 ) $ 8,324,714 See accompanying notes to consolidated financial statements. FS-6 Table of Contents BIOMERICA, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS Year ended May 31, 2022 2021 Cash flows from operating activities: Net loss $ ( 4,531,044 ) $ ( 7,446,254 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 339,096 138,267 Loss on disposal of property and equipment 52,587 - Provision for allowance on accounts receivable ( 684,184 ) 766,434 Inventory reserve ( 771,736 ) 1,550,594 Stock option expense 1,260,195 1,354,609 Amortization of right-of-use asset 255,725 237,588 Changes in assets and liabilities: Accounts receivable 1,365,417 ( 455,614 ) Inventories 1,561,544 ( 1,906,013 ) Prepaid expenses and other 50,007 1,138,793 Reduction in lease liability ( 244,412 ) ( 241,132 ) Other assets 168,563 ( 95,958 ) Accounts payable and accrued expenses 388,992 ( 403,331 ) Accrued compensation 258,048 110,269 Advance from customers 50,670 - Net cash used in operating activities ( 480,532 ) ( 5,251,748 ) Cash flows from investing activities: Expenditure related to intangibles ( 113,436 ) ( 159,727 ) Purchases of property and equipment ( 56,900 ) ( 135,856 ) Net cash used in investing activities ( 170,336 ) ( 295,583 ) Cash flows from financing activities: Gross proceeds from sale of common stock 2,401,734 1,177,394 Costs from sale of common stock ( 84,574 ) ( 165,919 ) Proceeds from exercise of stock options 77,360 102,255 Net cash provided by financing activities 2,394,520 1,113,730 Effect of exchange rate changes in cash ( 25,980 ) ( 8,115 ) Net increase (decrease) in cash and cash equivalents 1,717,672 ( 4,441,716 ) Cash and cash equivalents at beginning of year 4,199,311 8,641,027 Cash and cash equivalents at end of year $ 5,916,983 $ 4,199,311 Supplemental Disclosure of Cash Flow Information: Cash paid during the year for: Income taxes $ 23,719 $ 27,171 Non-cash investing and financing activities: Increase in right-of-use asset due to lease extension or establishment $ 4,478 $ 79,159 Increase in lease liability due to lease extension or establishment $ 4,478 $ 79,159 Write off of fixed assets, cost $ 819,931 $ - Write off of fixed assets, accumulated depreciation $ 767,344 $ - Write off of intangible assets, cost $ 246,756 $ - Write off of intangible assets, accumulated amortization $ 37,221 $ - See accompanying notes to consolidated financial statements FS-7 Table of Contents BIOMERICA, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS YEARS ENDED MAY 31, 2022 AND 2021 NOTE 1: ORGANIZATION Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians' offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases . Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (“DGT”) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. Our InFoods® IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods® IBS product works by identifying a patient’s above normal immunoreactivity to specific foods. A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores like Walmart and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic , in March 2020 we began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we offer a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues in fiscal 2022 have come from international sales of our COVID-19 antigen tests that use a patient’s nasal fluid sample to detect if the patient is currently infected with the virus. The other existing products that contributed to our 2022 revenues are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country’s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA. NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES PRINCIPLES OF CONSOLIDATION The consolidated financial statements for the years ended May 31, 2022 and 2021, include the accounts of Biomerica, Inc. ("Biomerica") as well as its wholly-owned German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. ACCOUNTING ESTIMATES The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. FS-8 Table of Contents Due to the Coronavirus global pandemic, the Company’s operations have been negatively impacted. The Company has faced disruptions in the following areas, (and may face further challenges): supply chain disruptions, loss of contracts and/or customers, closure of the Company’s manufacturing or distribution facilities or of the facilities of the Company’s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions can materially negatively impact the Company’s operations and financial performance and may continue to have significant material negative impacts on the Company. LIQUIDITY The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $ 35.3 million as of May 31, 2022. Management expects to continue to incur significant costs as it advances its trials and development activities. As of May 31, 2022, the Company had cash and cash equivalents of approximately $ 5,917,000 and working capital of approximately $ 7,416,000 . On January 22, 2021, the Company filed a Prospectus Supplement for purposes of raising up to $ 15,000,000 to the base prospectus filed with the SEC on July 21, 2020, and was declared effective by the SEC on September 30, 2020, and an ATM “at the market offering” Agreement. The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies, and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs. Under an ATM Agreement, sales of the Placement Shares are deemed to be “at the market offering” as defined in Rule 415 promulgated under the Securities Act. The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company’s behalf all the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement. During the year ended May 31, 2022, the Company sold 521,267 shares of its common stock at prices ranging from $ 4.02 to $ 5.63 under its Form S-3 Registration Statement ( File No. 333-239980) and ATM Agreement which resulted in gross proceeds of approximately $ 2,402,000 and net proceeds to the Company of $ 2,317,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3. As a result of cash and cash equivalents on hand on May 31, 2022, and the ability to raise additional funds through the ATM noted above, management believes the Company has sufficient funds to operate through at least August 2023. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable, and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values. The Company also maintains an investment in privately held company (see below). CONCENTRATION OF CREDIT RISK The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. As of May 31, 2022, the Company had approximately $ 5,702,000 of uninsured cash. The Company does not believe it is exposed to any significant credit risks. The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. Our net sales were approximately $ 18,871,000 for fiscal 2022 compared to $ 7,199,000 for fiscal 2021. For the fiscal years ended May 31, 2022 and 2021, the Company had two distributors, which accounted for a total of 65 % and 60 % of our net sales, respectively. Of this, for the fiscal years ended May 31, 2022 and 2021, the largest of the distributors mentioned above accounted for 55 % and 33 %, respectively, of net sales. FS-9 Table of Contents Total gross receivables on May 31, 2022 and 2021 were approximately $ 927,000 and $ 2,292,000 , respectively. On May 31, 2022 and 2021, the Company had one distributor and two distributors, respectively, which accounted for a total of 50 % and 73 %, respectively, of gross accounts receivable. Of the 50% as of May 31, 2022, 50 % was owed by a distributor in Asia. For the fiscal years ended May 31, 2022 and 2021, the Company had one vendor, which accounted for 84 % and 58 %, respectively, of our purchases of raw materials. GEOGRAPHIC CONCENTRATION As of May 31, 2022 and 2021, a pproximately $ 621,000 and $ 803,000 , respectively of Biomerica’s gross inventory was located in Mexicali, Mexico, respectively. As of May 31, 2022 and 2021, approximately $ 17,000 and $ 25,000 , respectively of Biomerica’s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively. CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months. ACCOUNTS RECEIVABLE The Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured. Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders. As of May 31, 2022 and 2021, the Company has established a reserve of approximately $ 153,000 and $ 837,000 , respectively, for doubtful accounts. PREPAIDS The Company occasionally prepays for items such as inventory, insurance, and other items. These items are reported as prepaids, until either the inventory is physically received or the insurance and other items are utilized. As of May 31, 2022 and 2021, the prepaids were approximately $ 320,000 and $ 370,000 , respectively, composed of prepayments to insurance and various other suppliers. INVENTORIES, NET The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. The following is a summary of approximate net inventories: May 31, 2022 2021 Raw materials $ 1,717,000 $ 1,812,000 Work in progress 763,000 1,687,000 Finished products 782,000 1,324,000 Total gross inventory $ 3,262,000 $ 4,823,000 Inventory reserve ( 846,000 ) ( 1,617,000 ) Net inventory $ 2,416,000 $ 3,206,000 FS-10 Table of Contents Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of May 31, 2022 and 2021, inventory reserves were approximately $ 846,000 and $ 1,617,000 , respectively. During the fiscal 2022 the Company disposed of COVID-19 antibody inventory that wasn’t sellable, this has been partially reserved for in fiscal 2021. The reduction in our inventory reserve relates to the COVID-19 antibody disposal. The Company continues to sell COVID-19 antigen tests. PROPERTY AND EQUIPMENT, NET Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to approximately $ 100,000 and $ 105,000 for the years ended May 31, 2022 and 2021, respectively. INTANGIBLE ASSETS, NET Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to approximately $ 239,000 and $ 34,000 for the years ended May 31, 2022 and 2021, respectively. The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of May 31, 2022 and 2021, an impairment adjustment was made of $ 210,000 and $ 0 , respectively. INVESTMENTS From time-to-time, the Company makes investments in privately held companies. Investments represent the Company’s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6 % of the investee and, accordingly, applies the cost method holdings to account for the investment. The Company invested approximately $ 165,000 into the Polish distributor. Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income. The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of May 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company’s Cost Method Holding during the year ended May 31, 2022. SHARE-BASED COMPENSATION The Company follows the guidance of ASC 718, Share-based Compensation (“ASC 718”), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company’s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method. The Company expensed approximately $ 1,260,000 and $ 1,355,000 of stock-based compensation during the years ended May 31, 2022 and 2021, respectively. FS-11 Table of Contents In applying the Black-Scholes options-pricing model, assumptions used were as follows: For the year ended May 31, 2022 2021 Dividend yield 0 % 0 % Expected volatility 102.54 - 105.48 % 71.19 - 107.53 % Risk free interest rate 0.97 - 2.75 % 0.34 - 1.18 % Expected term 5.50 - 6.25 Years 5.50 - 6.25 Years REVENUE RECOGNITION The Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred, and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company regularly evaluates the status of these contracts and does not believe that any additional discounts will be given through the end of the contract periods. Services for contract work are invoiced and recognized for work that has been performed as the project progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools, and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physicians’ office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. Disaggregation of revenue: The following is an approximate breakdown of revenues according to primary markets to which the products are sold: For the year ended May 31, 2022 2021 Physician's office $ 14,259,000 $ 2,801,000 Clinical lab 3,064,000 3,077,000 Over-the-counter 1,089,000 766,000 Contract manufacturing 459,000 555,000 Total $ 18,871,000 $ 7,199,000 See Note 8 for additional information regarding geographic revenue concentrations. SHIPPING AND HANDLING FEES The Company includes shipping and handling fees billed to customers in net sales. RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The Company expensed approximately $ 1,812,000 and $ 2,194,000 of research and development costs during the years ended May 31, 2022 and 2021, respectively. INCOME TAXES The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. On May 31, 2022 and 2021, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its net deferred tax assets. During the fiscal year ended May 31, 2022, this valuation allowance was increased to $ 6,967,000 , which fully covers the net tax asset of $ 6,967,000 . FS-12 Table of Contents The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement, the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company’s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. The Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the “Interest expense” line and penalties related to liabilities for income taxes within the “Other expense” line of the consolidated statements of operations and comprehensive loss. ADVERTISING COSTS The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately $ 76,000 and $ 10,000 for the years ended May 31, 2022 and 2021, respectively. FOREIGN CURRENCY TRANSLATION The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the years ended May 31, 2022 and 2021. RIGHT-OF-USE ASSETS AND LEASE LIABILITY In February 2016, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. Leases are classified as financing or operating which will drive the expense recognition pattern. The Company has elected to exclude short-term leases. The Company adopted this guidance as of June 1, 2019, the required effective date, which resulted in a right-of-use asset being recorded of approximately $ 1,943,000 and a lease liability being recorded of approximately $ 1,981,000 . On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years. As part of that lease extension agreement, the Company was granted an additional right to extend its lease for five years, up through August 2031. However, given the recent growth in the Company’s operations, and the expectation that operations will continue to grow in the near future, the Company believes that it will be necessary to relocate into larger facilities by the end of the current lease term. Therefore, the Company has elected to not include the additional five-year extension option, from August 2026 to August 2031, into its right-of-use asset or its lease liability accounts. For additional information, see Note 9-Commitments and Contingencies. The Company leases office space and copy machines, all of which are operating leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term. NET LOSS PER SHARE Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2022 and 2021 were 2,321,616 and 2,081,366 , respectively. FS-13 Table of Contents SEGMENT REPORTING ASC 280, Segment Reporting (“ASC 280”), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company’s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing, and sales of diagnostic kits. REPORTING COMPREHENSIVE LOSS Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders’ equity. Items of other comprehensive loss consist solely of foreign currency translation adjustments for the years ended May 31, 2022 and 2021. RECENT ACCOUNTING PRONOUNCEMENTS Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201·9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company’s consolidated results of operations and financial position. RECLASSIFICATIONS Certain comparative figures in the 2021 Statement of Operations have been reclassified to conform to the current year’s presentation. NOTE 3: PROPERTY AND EQUIPMENT, NET The following is an approximate breakdown of property and equipment, net of accumulated depreciation: May 31, 2022 2021 Equipment $ 1,292,000 $ 1,850,000 Furniture, fixtures and leasehold improvements 227,000 433,000 Less accumulated depreciation ( 1,305,000 ) ( 1,972,000 ) Net property and equipment $ 214,000 $ 311,000 NOTE 4: INTANGIBLE ASSETS, NET The following is an approximate breakdown of intangible assets, net of accumulated amortization: May 31, 2022 2021 Licenses $ - $ 182,000 Patents 189,000 240,000 Less accumulated amortization-licenses - ( 107,000 ) Less accumulated amortization-patents ( 19,000 ) ( 20,000 ) Intangible asssets, net $ 170,000 $ 295,000 Expected amortization of intangible assets for the years ending May 31: 2023 $ 13,000 2024 13,000 2025 13,000 2026 13,000 2027 13,000 Thereafter 105,000 Total $ 170,000 FS-14 Table of Contents NOTE 5: ACCOUNTS PAYABLE AND ACCRUED EXPENSES The following is an approximate breakdown of accounts payable and accrued expenses balances: May 31, 2022 2021 Accounts payable $ 736,000 $ 431,000 Accrued expenses 236,000 152,000 Total $ 972,000 $ 583,000 As of May 31, 2022 and 2021 the Company had two vendors and one vendor, respectively, which accounted for 69 % and 17 %, respectively, of accounts payable. NOTE 6: SHAREHOLDERS' EQUITY STOCK OPTION AND RESTRICTED STOCK PLANS In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees, or consultants of the Company. This plan was approved by shareholders in December 2014. The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80 % of the then fair market value of the common stock and will expire not more than 10 years after the date of grant. In December 2017, the Company adopted a stock option and restricted stock plan (the “2017 Plan”) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company’s unissued common stock may be granted to affiliates, employees, or consultants of the Company. This plan was approved by shareholders in December 2017. The 2017 Plan expires in December 2027. Options granted under the 2017 Plan will be granted at prices not less than 80 % of the then fair market value of the common stock and will expire not more than 10 years after the date of grant. In February 2020, the Board approved the 2020 Stock Incentive Plan (the “2020 Plan”) and on December 11, 2020, the shareholders of the Company approved The Plan. The 2020 Plan authorizes the issuance of an aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000 . The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors, and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan. Stock option expense during fiscal 2022 was approximately $ 1,260,000 . This included, by department, $ 954,000 for administrative, $ 159,000 for production, $ 80,000 for research and development and $ 67,000 for sales and marketing. Stock option expense during fiscal 2021 was approximately $ 1,355,000 . This included, by department, $ 957,000 for administrative, $ 205,000 for production, $ 125,000 for research and development and $ 68,000 for sales and marketing Activity as to aggregate stock options outstanding is as follows: NUMBER OF STOCK OPTIONS EXCERCISE PRICE RANGE PER SHARE WEIGHTED AVERAGE EXERCISE PRICE Options outstanding at May 31, 2020 1,789,251 $0.82-$8.18 $ 2.75 Options granted 430,616 $5.14-$8.70 $ 6.73 Options excercised ( 86,750 ) $0.82-$3.62 $ 1.20 Options canceled or expired ( 51,751 ) $2.35-$8.18 $ 4.77 Options outstanding at May 31, 2021 2,081,366 $0.82-$8.70 $ 3.59 Options granted 344,000 $4.25-$4.46 $ 4.43 Options excercised ( 39,500 ) $1.20-$3.62 $ 1.99 Options canceled or expired ( 64,250 ) $1.61-$8.18 $ 4.41 Options outstanding at May 31, 2022 2,321,616 $0.82-$8.70 $ 3.72 FS-15 Table of Contents The weighted average fair value of options granted during 2022 and 2021 were $ 4.43 and $ 6.73 , respectively. The aggregate intrinsic value of options exercised during 2022 and 2021 was approximately $ 90,000 and $ 501,000 , respectively. The aggregate intrinsic value of options outstanding on May 31, 2022 and 2021 was approximately $ 1,838,000 and $ 2,132,000 , respectively. The aggregate intrinsic value of options vested and exercisable on May 31, 2022 and 2021 was approximately $ 1,731,000 and $ 1,872,000 , respectively. The number of non-vested stock options included in the table above is as follows: Number of shares Stock options weighted average grant date fair value Non-vested shares at May 31, 2021 793,241 $ 5.54 Granted 344,000 4.43 Vested ( 347,279 ) 5.40 Forfeited ( 43,500 ) 5.22 Non-vested shares at May 31, 2022 746,462 $ 5.11 On May 31, 2022, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $ 1,982,000 . The weighted-average period over which this amount is expected to be recognized is 2.32 years. The weighted average remaining contractual term of options that were exercisable on May 31, 2022, was 5.47 years. The following summarizes information about all the Company's stock options outstanding on May 31, 2022. These options are comprised of those granted under the 2014, 2017 and 2020 plans. RANGE OF EXERCISE PRICES NUMBER OUTSTANDING MAY 31, 2022 WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE IN YEARS WEIGHTED AVERAGE EXERCISE PRICE NUMBER EXCERCISABLE AT MAY 31, 2022 WEIGHTED AVERAGE EXERCISE PRICE $ 0.82 -$ 1.52 456,000 3.33 $ 1.04 456,000 $ 1.04 $ 2.25 -$ 4.25 1,015,750 6.14 $ 2.90 852,500 $ 2.88 $ 4.34 -$ 8.70 849,866 8.75 $ 6.13 266,654 $ 7.06 COMMON STOCK ACTIVITY On January 22, 2021, the Company filed a Prospectus Supplement, for purposes of raising up to $ 15,000,000 to the base prospectus filed with the SEC on July 21, 2020, and declared effective by the SEC on September 30, and an ATM Agreement. On May 21, 2021, in conjunction with the Company’s 2020 Stock Incentive Plan, that was approved by shareholders at the Company’s annual meeting in December 2020, the Company filed an S-8 Registration Statement to register up to 900,000 shares of the Company’s common stock that could be issued under this Plan. Under ATM Agreements, sales of the Placement Shares are deemed to be “at the market offering” as defined in Rule 415 promulgated under the Securities Act. The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company’s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement. During the year ended May 31, 2022, the Company sold 521,267 shares of its common stock at prices ranging from $ 4.02 to $ 5.63 under its Form S-3 Registration Statement ( File No. 333-239980) and ATM Agreement which resulted in gross proceeds of approximately $ 2,402,000 and net proceeds to the Company of $ 2,317,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3. During the year ended May 31, 2021, the Company sold 158,889 shares of its common stock at prices ranging from $ 7.06 to $ 7.79 under its Form S-3 Registration Statement (File No. 333-239980) and ATM Agreement which resulted in gross proceeds of approximately $ 1,177,000 and net proceeds to the Company of $ 1,011,000 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3. During the year ended May 31, 2022, options to purchase 39,500 shares of common stock were exercised at prices ranging from $ 1.20 to $ 3.62 . Total net proceeds to the Company were approximately $ 77,000 . During the year ended May 31, 2021, 321,429 shares of common stock were converted from Preferred Stock as described below in “Preferred Stock Activity”. PREFERRED STOCK ACTIVITY On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Palm Global Small Cap Master Fund LP (“Palm”) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company’s Series A 5% Convertible Preferred Stock, $ 0.08 par value per share for a purchase price of approximately $ 2 million, or $ 3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company’s common stock, subject to certain adjustments. The Series A 5% Convertible Preferred Stock accrued annual preferred dividends at a rate of $ 0.175 per Series A 5% Convertible Preferred Share. However, accruing dividends were payable only when, as, and if declared by the Board and the Company had no obligation to pay such accruing dividends. On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3, that among other things, registered 571,429 common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. On September 30, 2020, the Company received a Notice of Effectiveness from the Securities and Exchange Commission for registration of these shares. On January 21, 2021, Palm Converted their remaining 321,429 Convertible Preferred Shares into registered common shares. On May 30, 2021, the Company had no shares of Preferred Stock outstanding. Under the terms of the Preferred Stock Purchase Agreement, none of the cumulative Dividends were paid to Palm during the period they owned the Preferred Stock. Once converted to common shares, Palm lost all rights to receive any past cumulative dividends. FS-16 Table of Contents NOTE 7: INCOME TAXES Provision for income taxes for the years ended May 31 consists of the following: For the year ended May 31, 2022 2021 Current: U.S. Federal $ - $ - Foreign Taxes Subsidiaries ( 23,000 ) ( 12,000 ) State and local ( 1,000 ) ( 1,000 ) Total current ( 24,000 ) ( 13,000 ) Deferred: U.S. Federal - - State and local - - Total deferred - - Income tax expense $ ( 24,000 ) $ ( 13,000 ) Provision for income taxes differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year ( 21 % for 2022 and 2021) to pretax income as a result of the following: For the year ended May 31, 2022 2021 Computed "expected" tax benefit $ 947,000 $ 1,561,000 Increase (reduction) in income taxes resulting from: Change in valuation allowance ( 1,022,000 ) ( 2,292,000 ) State income taxes, net of federal benefit 300,000 217,000 Research and development tax credits 50,000 456,000 Permanent tax differences and other ( 217,000 ) ( 88,000 ) Stock based compensation benefit 11,000 145,000 Foreign taxes of subsidiaries ( 113,000 ) ( 12,000 ) Income tax expense $ ( 24,000 ) $ ( 13,000 ) The tax effect of significant temporary differences is presented below: May 31, 2022 2021 Deferred tax assets: Accounts receivable, principally due to allowance for doubtful accounts $ 43,000 $ 200,000 Inventory valuation 237,000 387,000 Compensated absences 120,000 85,000 Net operating loss carryforwards 4,349,000 3,194,000 Tax credit carryforwards 1,096,000 1,055,000 Deferred rent expense/Capitalized leases 20,000 15,000 Stock Options 1,035,000 613,000 Losses of foreign subsidiaries & Other, net 41,000 370,000 Accumulated depreciation and amortization 26,000 ( 15,000 ) Total deferred tax assets 6,967,000 5,904,000 Less valuation allowance ( 6,967,000 ) ( 5,904,000 ) Net deferred tax asset $ - $ - The Company has provided a valuation allowance of approximately $ 6,967,000 and $ 5,904,000 as of May 31, 2022 and 2021, respectively. The net change in the valuation allowance for the years ended May 31, 2022 and 2021, was an increase of $ 1,063,000 and $ 2,292,000 , respectively. On May 31, 2022, the Company has Federal income tax net operating loss carryforwards of approximately $ 17,116,000 . On May 31, 2022, the Company has California state income tax net operating loss carryforwards of approximately $ 10,805,000 . For tax reporting purposes, operating loss carryforwards are available to offset future taxable income; such carryforwards expire in varying amounts beginning in 2023 and 2037 for federal and state purposes, respectively. Federal net operating losses beginning in 2018 have no expiration date. FS-17 Table of Contents On May 31, 2022, the Company has Federal research and development tax credit carryforward of approximately $ 784,000 . The Federal credits begin to expire in 2027 . The Company also had similar credit carryforwards for state purposes of $ 395,000 on May 31, 2022, which don’t expire. Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%. For the year ended May 31, 2022, the Company did an analysis of its ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740 . Should such position be identified in the future, and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal 2018 . NOTE 8: GEOGRAPHIC INFORMATION The Company operates as one segment. Geographic information regarding net sales is approximately as follows: For the year ended May 31, 2022 2021 Asia $ 13,375,000 71 % $ 1,908,000 26 % Europe 4,339,000 23 % 4,301,000 60 % North America 997,000 5 % 548,000 8 % South America 90,000 1 % 250,000 3 % Middle East 70,000 0 % 192,000 3 % Total $ 18,871,000 100 % $ 7,199,000 100 % NOTE 9: COMMITMENTS AND CONTINGENCIES OPERATING LEASES The Company leases its facilities. On May 31, 2022, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021 . On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years. When the Company extended its lease in April 2021, it was also granted an additional five-year lease extension option. The current rent is approximately $ 25,000 per month and will increase on September 1, 2022, to $ 26,000 per month. The security deposit is approximately $22,000. In November 2016, the Company’s Mexican subsidiary, Biomerica de Mexico, entered into a 10 -year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. The current rent is approximately $ 3,400 per month. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary. Total gross rent expense in the United States for fiscal 2022 was approximately $ 310,000 , and for fiscal 2021 was $ 295,000 . Rent expense for the Mexico facility for fiscal 2022 and 2021 was approximately $ 42,000 and $ 25,000 , respectively. For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company’s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability. Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred. FS-18 Table of Contents Supplemental cash flow information related to leases for the year ended May 31, 2022: Operating cash flows from operating leases $ 338,206 Right-of-use assets obtained in exchange for new operating lease liabilities $ - Weighted average remaining lease term (in years) 4.28 Weighted average discount rate 6.50 % Future minimum lease payments under operating leases on May 31, 2022, are as follows: Less than 1 year $ 351,000 1 to 2 years 362,000 2 to 3 years 373,000 3 to 4 years 384,000 4 to 5 years 104,000 Total undiscounted lease payments 1,574,000 Less imputed interest 194,000 Total operating lease liabilities $ 1,380,000 According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. The Company also has various insignificant leases for office equipment. RETIREMENT SAVINGS PLAN Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception. LITIGATION The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of May 31, 2022. CONTRACTS Contracts and Licensing Agreements The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $ 19,000 and $ 11,000 is included in cost of sales for the agreement for each of the years ended May 31, 2022 and 2021, respectively. Sales of products manufactured under these agreements comprise approximately 1.5 % and 1.5 % of total sales for the years ended May 31, 2022 and 2021, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business. The Company has other royalty agreements however they are not considered material. FS-19 Table of Contents On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (“Telcon Agreement”) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (“Telcon”), a medical company in South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica’s new InFoods® IBS products (“IBS Products”) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. The required FDA approval was not obtained by December 31, 2019, however, neither party has terminated the agreement. Once the IBS Product is cleared by the United States FDA, Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. The terms of the Telcon Agreement provide up to $ 1.25 million in future exclusivity fees to be possibly paid to Biomerica based on certain milestones including Biomerica’s starting clinical trials in the United States, receipt of U.S. FDA clearance and Telcon’s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common stock in consideration for the $ 250,000 of paid exclusivity fee. No exclusivity fees have yet been paid. Additionally, the Telcon Agreement provides for a royalty of 15 % paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon. In order to retain the exclusivity within South Korea, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon’s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019. In September 2017, an agreement to extend this date was signed extending the date until April 30, 2020. During the quarter ended August 31, 2020, a second amendment was signed extending the required FDA approval date to December 31, 2021. The required FDA approval date hasn’t been delivered however, neither party has terminated the agreement. On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the “Mount Sinai License Agreements”) with the Mount Sinai Icahn School of Medicine in New York (“Mount Sinai”) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus. The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for Emergency Use Authorization (“EUA”) with the FDA for the sale of a product developed by the Company that is based on this technology. The FDA has still not approved the Company’s Emergency Use Authorization for this product to be sold. As such, no royalty fees have been paid yet on these agreements. The Company is selling a COVID-19 rapid test outside of the United States, which is unrelated to the EUA product discussed above. On May 7, 2020, the Company entered into an exclusive license agreement (the “UC License Agreement”) with The Regents of the University of California (“UC”) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at UC-San Diego by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus. If this technology development is successful, the Company will work with the UC to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated, and cleared with regulatory agencies for commercial sale into the market. The exclusive UC License Agreement provides for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $ 5,000 with the execution of the agreement. An additional $ 5,000 was paid in September 2020. No royalties have been paid yet on this agreement. A license maintenance fee of $ 10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products. Clinical Trial Agreements In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing. The initial budget was estimated to be approximately $ 82,000 . The work started in October 2017 with charges for work performed being invoiced and paid monthly. This study ended in February 2020. Approximately $ 17,000 in fees has been accrued for unbilled charges as of May 31, 2022. The Company entered into a Clinical Trial Agreement with a research institute for the purpose of conducting a clinical trial of the Biomerica InFoods® product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $ 107,000 . This study ended in March 2022. Approximately $ 28,000 in fees has been accrued for unbilled charges as of May 31, 2022. FS-20 Table of Contents NOTE 10: SUBSEQUENT EVENTS Subsequent to May 31, 2022, as of the filing of Form 10-K, the Company sold 523,977 shares of its common stock under its Form S-3 “shelf” Registration statement. The average sale price was $ 3.46 per share. Net proceeds to the Company were approximately $ 1,765,000 . On July 14, 2022, the Company announced they had entered into a General Merchandise Supplier Agreement with Walmart, for the Company’s Aware ® Breast Self Exam product to be sold in Walmart’s retail system. FS-21